Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-Ro 43-Gil, Songpa-gu, Seoul, 138-736, Korea.
Anticancer Res. 2013 Dec;33(12):5667-73.
We examined the relationship between p16, a surrogate marker of human papilloma virus (HPV), and FOXP3, marker of regulatory T-cells, in tonsillar squamous cell carcinoma (TSCC), and assessed their prognostic potential.
The tumors of 79 patients with locally advanced TSCC treated from 2000 to 2008 were subjected to immunohistochemistry (IHC) assays for p16 and FOXP3 using tissue microarrays.
Sixty-three tumors (80%) were p16-positive and 38 (48%) were FOXP3-positive on IHC. FOXP3 correlated positively with p16 (p=0.011). The p16-positive group had a significantly higher 5-year overall survival (OS) rate than the p16-negative group [78% vs. 63%, hazard ratio (HR)=0.347, p=0.025]. The FOXP3-positive group had a significantly higher 5-year OS rate than the - negative group (89% vs. 61%, HR=0.158, p=0.003). Multivariate analysis indicated that FOXP3 is an independent prognostic factor (HR=0.11, p=0.001) but p16 did not reach statistical significance (HR=2.17, p=0.131).
FOXP3 expression is associated positively with p16 expression, and is a favorable prognostic factor for survival in TSCC.
我们研究了人乳头瘤病毒（HPV）替代标志物 p16 和调节性 T 细胞标志物 FOXP3 在扁桃体鳞状细胞癌（TSCC）中的关系，并评估了它们的预后潜力。
对 2000 年至 2008 年期间接受治疗的 79 例局部晚期 TSCC 患者的肿瘤进行了组织微阵列免疫组化（IHC）检测 p16 和 FOXP3。
63 例肿瘤（80%）p16 阳性，38 例（48%）FOXP3 阳性。FOXP3 与 p16 呈正相关（p=0.011）。p16 阳性组的 5 年总生存率（OS）显著高于 p16 阴性组[78%比 63%，风险比（HR）=0.347，p=0.025]。FOXP3 阳性组的 5 年 OS 率显著高于阴性组（89%比 61%，HR=0.158，p=0.003）。多变量分析表明，FOXP3 是独立的预后因素（HR=0.11，p=0.001），但 p16 未达到统计学意义（HR=2.17，p=0.131）。
FOXP3 表达与 p16 表达呈正相关，是 TSCC 患者生存的有利预后因素。
